Cardiovascular and Metabolic Risk

Post–Glucose Load Plasma α-Dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study

  1. Dionne E. Maessen1,2,
  2. Nordin M. Hanssen1,2,
  3. Jean L. Scheijen1,2,
  4. Carla J. van der Kallen1,2,
  5. Marleen M. van Greevenbroek1,2,
  6. Coen D. Stehouwer1,2 and
  7. Casper G. Schalkwijk1,2⇑
  1. 1CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, the Netherlands
  2. 2Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands
  1. Corresponding author: Casper G. Schalkwijk, c.schalkwijk{at}maastrichtuniversity.nl.
Diabetes Care 2015 May; 38(5): 913-920. https://doi.org/10.2337/dc14-2605

Abstract

OBJECTIVE There is increasing evidence that postprandial glucose excursions play an important role in the development of vascular complications. The underlying mechanism is unknown, but glucose-derived formation of reactive α-dicarbonyl compounds may explain why acute hyperglycemia leads to increased risk for diabetes complications. In the current study, we investigated whether α-dicarbonyls are increased after a glucose load in individuals without or with impaired glucose metabolism (IGM) and type 2 diabetes.

RESEARCH DESIGN AND METHODS Cross-sectional, linear analyses were performed in the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM [n = 574, 61% men, 60 years old]) study. Individuals with normal glucose metabolism (n = 279), IGM (n = 120), and type 2 diabetes (n = 92) who had complete data on an oral glucose tolerance test (OGTT) and were not on insulin treatment were included in the study population. Plasma α-dicarbonyl (methylglyoxal [MGO], glyoxal [GO], and 3-deoxyglucosone [3-DG]) levels were measured in the fasting state and in samples of the OGTT by ultra-performance liquid chromatography–tandem mass spectrometry.

RESULTS The presence of both IGM and type 2 diabetes was significantly associated with higher α-dicarbonyl incremental areas under the curve (iAUCs), as calculated from the OGTT (for IGM, MGO β = 0.190 [95% CI 0.106–0.274], GO β = 0.287 [95% CI 0.172–0.401], and 3-DG β = 0.285 [95% CI 0.221–0.349]; for type 2 diabetes, MGO β = 0.293 [95% CI 0.180–0.405], GO β = 0.536 [95% CI 0.382–0.689], and 3-DG β = 0.542 [95% CI 0.456–0.628]). Adjustment for glucose iAUC attenuated these associations. iAUCs of the α-dicarbonyls correlated highly with glucose iAUC but not with fasting glucose levels or HbA1c.

CONCLUSIONS The increased levels of α-dicarbonyls during an OGTT in individuals with IGM and type 2 diabetes underline the potential importance of α-dicarbonyl stress as a candidate to explain the increased risk of diabetes complications in individuals with postprandial hyperglycemia.

Introduction

Type 2 diabetes and impaired glucose metabolism (IGM) are associated with the development of microvascular complications and cardiovascular disease (CVD) (1). Prospective studies in diabetes have shown a strong correlation between mean glucose levels, as reflected by HbA1c, and diabetes complications. However, in recent years, postprandial glucose excursions, rather than fasting glucose concentrations or mean glucose levels, have increasingly been recognized as a contributing factor to the increased risk of vascular complications (2,3). Controlled clinical trials, such as the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes (4) and the UK Prospective Diabetes Study (UKPDS) in type 2 diabetes (5), have established that intensive therapies that reduce HbA1c levels reduce and delay the development and progression of diabetes-related long-term vascular complications. Posttrial analyses of the DCCT revealed that postmeal glucose levels contribute more to HbA1c than fasting plasma levels (6), suggesting that postprandial hyperglycemic spikes may accelerate the onset of diabetes complications. Moreover, many epidemiological data support this concept, showing that glucose levels after an oral glucose tolerance test (OGTT) are an independent risk factor for CVD while fasting glucose levels are not or are less so (2,7–11). In addition, postprandial glucose in type 2 diabetes predicts myocardial infarctions (12) and is a risk factor for CVD (13). However, it is largely unknown how these postprandial glucose peaks cause the increased risk for diabetes complications. A possible mechanism through which they have a more damaging effect than high fasting or mean glucose levels might be via the formation of α-dicarbonyls.

The α-dicarbonyls, methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucoseone (3-DG), are mainly formed as glycolytic intermediates by metabolic conversion of glucose. We and others have shown the importance of α-dicarbonyls in the development of nephropathy (14,15), retinopathy (16), and neuropathy (17,18) and in macrovascular complications (19), using rodent models of diabetes.

We hypothesized that the postprandial glucose concentrations, rather than fasting plasma glucose, determine α-dicarbonyl levels. Although Beisswenger et al. (20) already demonstrated, in a small study of 21 individuals with type 1 diabetes, that both MGO and 3-DG plasma levels increase after postprandial glycemic excursions, the question of whether α-dicarbonyl levels are elevated in individuals with impaired glucose metabolism (IGM) and type 2 diabetes remains unanswered.

In the current study, we investigated, in a large cohort study, whether plasma levels of α-dicarbonyls are elevated in individuals with IGM and type 2 diabetes. Both fasting levels and incremental areas under the curve (iAUCs) obtained from an OGTT were analyzed.

Research Design and Methods

Study Population

The current study comprises participants from the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study, which included 574 participants who were selected from the general population as previously described in detail (21). The CODAM study was designed to investigate cardiovascular and metabolic function and was enriched for IGM status, as previously described (22). Current main analyses were performed on 491 participants who underwent a full OGTT and were not on insulin treatment. The study was approved by the local Medical Ethics Committee of Maastricht University Medical Centre, and all participants gave written informed consent.

Definition of Glucose Metabolism Status

The glucose tolerance status of the participants was determined by an OGTT. After an overnight fasting period (10–12 h), study participants underwent a standard 75-g OGTT (82 g dextrose monohydrate; AVEBE, Veendam, the Netherlands) and venous blood was obtained prior to and at 30, 60, and 120 min after the glucose load. Fasting and postload plasma glucose concentrations (in millimoles per liter) were measured with a hexokinase glucose-6 phosphate dehydrogenase method (ABX Diagnostics, Montpellier, France). Fasting and 2-h postload glucose concentrations were used to classify the study participants’ glucose metabolism status (GMS) according to the World Health Organization criteria. Briefly, individuals were classified as having normal glucose metabolism (NGM) when they had normal fasting (<6.1 mmol/L) and 2-h postload (<7.8 mmol/L) glucose concentrations. Individuals with impaired fasting glucose (6.1–7.0 mmol/L), impaired 2-h postload glucose levels (7.8–11.1 mmol/L), or both were classified as having IGM. When individuals had high fasting plasma glucose levels (≥7.0 mmol/L) and/or high 2-h postload glucose levels (≥11.1 mmol/L) or when they used glucose-lowering medication or insulin, they were classified as having type 2 diabetes (22). Individuals with known type 2 diabetes or those with fasting glucose levels >8.5 mmol/L were excluded from undergoing an OGTT.

Measurements of Plasma α-Dicarbonyls

Plasma levels of α-dicarbonyls were measured in EDTA plasma samples from the OGTT at baseline and 30, 60, and 120 min after the glucose load. Blood samples were collected in EDTA tubes, which were stored on ice prior to blood sampling to ensure rapid cooling of the blood. After withdrawal of the blood sample, tubes were stored on ice immediately and were spun within 2 h at 3,000 rpm, 4°C. Plasma samples were stored at −80°C until analysis. Reversed-phase ultra-performance liquid chromatography–tandem mass spectrometry was used to analyze the plasma samples for MGO, GO, and 3-DG as previously described (23). The interassay variations for MGO, GO, and 3-DG were 4.3, 5.1, and 2.2%, respectively. Current analyses were performed with fasting α-dicarbonyl levels and OGTT iAUCs.

Calculation of the OGTT iAUC

The area under the curve for the OGTT levels of the α-dicarbonyls and glucose was calculated according to the trapezoidal method (24), where baseline (fasting) levels were subtracted from each individual data point to specify the post–glucose load increases. These data are referred to as the iAUC.

Covariates

Waist circumference and prior CVD were assessed as previously described (25). Questionnaires were used to assess smoking behavior (never, ever, or current smoker) and use of medication (lipid-, glucose-, and blood pressure–lowering medication). Plasma creatinine levels were measured with the Jaffe diagnostic test (Roche Diagnostics, Mannheim, Germany), and the estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (26). Systolic blood pressures were measured in the brachial arteries and twice in both the tibialis posterior and dorsalis pedis arteries of the lower extremities with a standard Doppler device (Mini Dopplex D900; Huntleigh Diagnostics Ltd., Harmelen, the Netherlands) (27). Total and HDL cholesterol and triglycerides were measured in EDTA plasma by enzymatic methods (Roche Diagnostics, Mannheim, Germany) (27).

Statistical Analyses

The general characteristics of the study population were compared across the three groups of GMS. Continuous variables were analyzed with one-way ANOVA, and discrete variables were analyzed with χ2 tests. Fasting levels and iAUCs from the OGTT were normally distributed for all α-dicarbonyls. For increase in statistical power, missing values on HbA1c (3.7% missing), eGFR (0.8% missing), and BMI (0.2% missing) were imputed by creating five data sets using multiple imputation. Skewed variables (fasting plasma glucose, fasting plasma insulin, HOMA of insulin resistance, and triglycerides) were loge transformed prior to analyses. Two-way repeated-measures ANOVA with Bonferroni correction was used to compare the curves of the α-dicarbonyls during the OGTT between NGM, IGM, and type 2 diabetes over time. Fasting levels and iAUCs of the α-dicarbonyls were compared between the groups using one-way ANOVA with Bonferroni correction. Multiple linear regression analysis was used to investigate potential influence of confounding factors on the association between GMS and α-dicarbonyl levels. The main independent variables were GMS, analyzed as dummies for IGM and type 2 diabetes, fasting glucose levels, iAUC glucose, and HbA1c, and the main dependent variables were fasting levels and iAUCs of the α-dicarbonyls. Data are presented as standardized regression coefficients (β). Analyses were initially adjusted for age and sex; analyses with fasting glucose levels, iAUC glucose, and HbA1c were also adjusted for GMS (model 1). Analyses were further adjusted for smoking status, eGFR, loge triglycerides, total-to-HDL cholesterol ratio, waist circumference, prior CVD, systolic blood pressure, and use of medication (lipid-, glucose-, and blood pressure–lowering medication) (model 2). Finally, analyses for GMS were additionally adjusted for glucose (fasting or iAUC glucose, appropriate to the α-dicarbonyl measure) as a potential source of α-dicarbonyl formation (model 3), and to investigate the extent to which iAUCs were dependent on fasting α-dicarbonyl levels, model 2 was additionally adjusted for fasting plasma levels of the appropriate α-dicarbonyl (model 4). A P value of <0.05 was considered statistically significant.

As increased levels of α-dicarbonyls can be a result of both increased formation and decreased detoxification, we investigated whether individuals with IGM or type 2 diabetes had a decreased capacity to detoxify α-dicarbonyls. To test this, we analyzed whether the association between postload glucose excursions and α-dicarbonyl iAUCs differed between individuals with NGM, IGM, or type 2 diabetes. To this end, the interaction terms IGM × iAUC glucose and type 2 diabetes × iAUC glucose were added to the linear regression model (adjusted for covariates in model 2). Pinteraction < 0.1 was considered statistically significant. Significant P values for interaction would indicate a different detoxification capacity of α-dicarbonyls in individuals with IGM or type 2 diabetes for the same change in glucose concentration.

All statistical analyses were performed with IBM SPSS Statistics Software, version 20 (IBM Corporation, Armonk, New York).

Results

General characteristics of the study population stratified according to GMS are shown in Table 1. Overall, participants with type 2 diabetes were slightly older; had a higher BMI, higher blood pressure, and lower HDL cholesterol; and had a higher incidence of CVD and microalbuminuria. Curves of the OGTT in Fig. 1 demonstrate increased levels of glucose and MGO, GO, and 3-DG after the glucose load. Plasma glucose levels were ∼5,000-fold higher compared with the plasma α-dicarbonyl levels.

View this table:
Table 1

General characteristics of the CODAM study population stratified according to glucose metabolism status

Figure 1
Figure 1

Plasma α-dicarbonyl and glucose levels during an OGTT. MGO levels during an OGTT over time (A) and these data calculated as an iAUC (B). C–H: The same for GO levels (C and D), 3-DG levels (E and F), and glucose levels (G and H). Data are shown as means ± SEM. ●, NGM; ■, IGM; ▲, type 2 diabetes. Differences in OGTT curves between the groups of GMS were tested with repeated-measures two-way ANOVA with Bonferroni correction. Differences in iAUCs between the groups were tested with one-way ANOVA with Bonferroni correction. ***P < 0.001, *P < 0.05 compared with NGM; ###P < 0.001, ##P < 0.01 compared with IGM.

Univariate Associations Between GMS and Both Fasting Plasma α-Dicarbonyls and the OGTT iAUC of the Plasma α-Dicarbonyls

When we analyzed the fasting α-dicarbonyl levels, we found ∼1.1-fold higher plasma concentrations of MGO in individuals with type 2 diabetes, but not with IGM (Table 1) (P < 0.001), compared with NGM. Fasting levels of 3-DG were increased in both individuals with IGM and individuals with type 2 diabetes compared with those with NGM (Table 1) (both P < 0.001). GO levels at baseline did not differ between the groups (Table 1).

When we additionally included individuals with known type 2 diabetes who were not allowed to undergo an OGTT, we observed significantly higher fasting levels of plasma α-dicarbonyls compared with levels from those who did undergo the OGTT (Supplementary Fig. 1).

iAUCs for the α-dicarbonyls MGO, GO, and 3-DG were significantly higher (1.6-, 2.3- and 1.8-fold change, respectively) in participants with IGM (all P < 0.001) and were even higher (2.1-, 3.4-, and 2.6-fold change, respectively) in those with type 2 diabetes (all P < 0.001) (Fig. 1B, D, and F) compared with NGM. For glucose, both fasting levels and iAUC of the OGTT were increased in individuals with IGM and type 2 diabetes (Table 1 and Fig. 1H) (all P < 0.001).

Multivariate Associations Between GMS and Fasting Plasma α-Dicarbonyl Levels

The presence of IGM was not associated with higher fasting plasma levels of MGO or GO after adjustment for age and sex (Table 2) (model 1). Fasting plasma 3-DG levels in individuals with IGM were 0.255 SD higher than in those with NGM (β = 0.255 [95% CI 0.136–0.375], P < 0.001). Additional adjustment for smoking, eGFR, triglycerides, total-to-HDL cholesterol ratio, waist circumference, medication use, prior CVD, and systolic blood pressure did not materially change this association (Table 2) (model 2). Addition of fasting glucose levels to the regression model completely attenuated the association between the presence of IGM and higher fasting levels of 3-DG (Table 2) (model 3).

View this table:
Table 2

Associations between glucose metabolism status and fasting and iAUC measures of plasma α-dicarbonyls during an OGTT

In contrast, the presence of type 2 diabetes was associated with higher fasting levels of both MGO (β = 0.542 [95% CI 0.322–0.761], P < 0.001) and 3-DG (β = 1.517 [95% CI 1.385–1.649], P < 0.001) after adjustment for age and sex compared with NGM. After additional adjustment for multiple covariates in model 2, associations between the presence of type 2 diabetes and higher fasting levels of MGO (β = 0.492 [95% CI 0.216–0.769], P < 0.001) and 3-DG (β = 1.376 [95% CI 1.211–1.542], P < 0.001) were largely unchanged. Further adjustment for fasting glucose levels resulted in an 82% attenuation of the association between type 2 diabetes and fasting MGO levels (Table 2) (model 3). In line, the association between type 2 diabetes and fasting 3-DG levels was attenuated by 61% but remained statistically significant (Table 2) (model 3). Also, after adjustment for potential confounders, we found no associations between either IGM or type 2 diabetes and fasting GO levels.

Multivariate Associations Between GMS and iAUCs of α-Dicarbonyls

In age- and sex-adjusted analyses, the presence of IGM was associated with significantly higher iAUCs for all three α-dicarbonyls (MGO β = 0.203 [95% CI 0.123–0.283], P < 0.001; GO β = 0.268 [95% CI 0.160–0.377], P < 0.001; and 3-DG β = 0.319 [95% CI 0.257–0.382], P < 0.001), compared with NGM. For type 2 diabetes, the associations with higher iAUCs of all three α-dicarbonyls appeared to be even stronger (MGO β = 0.359 [95% CI 0.271–0.448], P < 0.001; GO β = 0.486 [95% CI 0.366–0.606], P < 0.001; and 3-DG β = 0.645 [95% CI 0.576–0.714], P < 0.001). After further adjustment for the covariates in model 2, both IGM and type 2 diabetes remained significantly associated with higher iAUCs of all three α-dicarbonyls (Table 2) (model 2) compared with iAUCs of individuals with NGM. However, when analyses were further adjusted for the iAUC from glucose, the associations of both IGM and type 2 diabetes with MGO and 3-DG iAUCs disappeared completely (Table 2) (model 3). Similarly, although the association between type 2 diabetes and higher iAUC of GO (β = 0.180 [95% CI 0.001–0.358], P = 0.049) remained significant, it was also attenuated by 66%. Adjustment for fasting levels of the appropriate α-dicarbonyls in model 4 did not change the strength of the association compared with model 2 (Table 3) (model 4 vs. 2).

View this table:
Table 3

Associations of iAUC glucose, HbA1c, and fasting glucose with iAUC of plasma α-dicarbonyls

Since the associations between IGM and type 2 diabetes and higher α-dicarbonyl iAUCs almost completely disappeared after adjustment for glucose, we hypothesized that the higher iAUCs of MGO, GO, and 3-DG were a direct result of higher iAUCs of glucose in IGM and type 2 diabetes rather than a decreased capacity to detoxify α-dicarbonyls. Indeed, when adjusted for all covariates in model 2, the glucose iAUC was strongly associated with the iAUC of all three α-dicarbonyls (Table 3) (MGO β = 0.195 [95% CI 0.148–0.243], P < 0.001; GO β = 0.231 [95% CI 0.165–0.297], P < 0.001; and 3-DG β = 0.342 [95% CI 0.318–0.365], P < 0.001). These associations did not differ between NGM, IGM, or type 2 diabetes for all three α-dicarbonyls (Pinteraction > 0.1). Overall, associations between the iAUC of glucose and the iAUC of α-dicarbonyls were stronger than associations between HbA1c or fasting plasma glucose and the iAUC of α-dicarbonyls (Table 3).

Conclusions

This study demonstrates that iAUCs of the α-dicarbonyls MGO, GO, and 3-DG, as calculated from an OGTT, were higher in individuals with IGM and type 2 diabetes, independently of potential confounders. Fasting plasma levels of α-dicarbonyls were predominantly higher in individuals with type 2 diabetes, although fasting 3-DG levels were also slightly increased in individuals with IGM. After adjustment for glucose, these associations disappeared almost completely for MGO and 3-DG and to a large, but slightly lesser, extent for GO, indicating that glucose is the major source of α-dicarbonyls. To our knowledge, this is the first time that α-dicarbonyls have been measured in a post–glucose load setting in individuals with NGM, IGM, and type 2 diabetes.

In the current study, we found that iAUCs of MGO, GO, and 3-DG, as calculated from an OGTT, were higher in individuals with IGM and type 2 diabetes, independently of potential confounders. Our data are in accordance with findings from a previous study by Beisswenger et al. (20), in which they showed increased MGO and 3-DG levels during the postprandial period in patients with type 1 diabetes. As glucose serves as a primary source for the formation of α-dicarbonyls, transient glucose excursions during the postprandial period may give rise to increases of α-dicarbonyl levels, which in turn may induce long-term damage to the vasculature. Indeed, El-Osta et al. (28) demonstrated that even transient exposures to high glucose levels induce persistent changes in cultured endothelial cells, which could be prevented by an overexpression of glyoxalase I, the major enzyme detoxifying MGO and GO. We and others have demonstrated that increased levels of α-dicarbonyl compounds are directly associated with vascular complications (14,29). MGO particularly has attracted a lot of attention as a key player in vascular dysfunction as a result of its capacity to induce oxidative stress (29), cell death (30), and endothelial dysfunction (14). Therefore, the observed increased levels of α-dicarbonyls with postchallenge glucose excursions in IGM and type 2 diabetes may link fluctuations in blood glucose levels in these patients with persistent increases in risk of vascular complications and CVD.

The α-dicarbonyls in the plasma can originate from various sources, including in situ formation in the plasma, release from cells and external sources (31). Owing to their rapid increase during the OGTT, the postload plasma α-dicarbonyl levels most likely originate from intracellular compartments that come directly into contact with plasma glucose. As we found the largest increase in α-dicarbonyls in the individuals with IGM and with type 2 diabetes, it is likely that plasma α-dicarbonyls originate from insulin-independent cells, specifically, red blood cells and endothelial cells. Indeed, we demonstrated in human endothelial cells that hyperglycemia produced higher levels of MGO (32) and that α-dicarbonyl levels are much higher in circulating cells than in plasma (23). We assume that α-dicarbonyl levels after a glucose challenge would increase even further in circulating cells and endothelial cells, as only a small percentage of dicarbonyl compounds leaks into the circulation (23). To what extent this increase of dicarbonyls in plasma is similar in other tissues that are sensitive to diabetes complications, such as the kidney, nerves, retina, and atherosclerotic plaques, remains to be elucidated. Next to release from cells, plasma α-dicarbonyls may also be a result of autoxidation of glucose in the plasma, but it is not known to what extent this process contributes to plasma levels of α-dicarbonyls. It is unlikely, however, that the iAUCs reflect any autoxidation, as this is a slow process and we observed an increase of α-dicarbonyls already 30 min after the glucose load. In addition, dicarbonyl compounds can also originate from exogenous sources (31), for example, from the glucose drink we used in this study. However, we previously observed no increased plasma MGO levels in a healthy volunteer within 2 h after drinking coffee, a drink with very high levels of MGO (55 µmol/L) but without any glucose. As the glucose drink used for the OGTT only contained 1.6 µmol/L MGO, it is highly unlikely that the low levels of α-dicarbonyls in the glucose drink contribute to their plasma levels after the glucose challenge. The question remains whether the increased α-dicarbonyl iAUCs are a reflection of decreased detoxification potency in IGM and type 2 diabetes. The glyoxalase system is the major pathway to detoxify MGO and GO (33). This system consists of the rate-limiting enzyme glyoxalase-1 and glyoxalase-2. These enzymes convert MGO and GO, with the involvement of reduced glutathione, to their end product d-lactate (33). Several experimental studies have linked the presence of diabetes to dysfunction of the glyoxalase system (34). However, additional adjustment for glucose in our analyses attenuated the associations between GMS and the iAUC of α-dicarbonyls by 60–97%, suggesting that the elevated postchallenge dicarbonyl levels are the result of increased formation from its substrate glucose. Although dysfunction of α-dicarbonyl detoxification cannot be eliminated as a contributor to increased plasma α-dicarbonyl levels, the lack of interaction between dicarbonyl iAUCs and GMS indicates that detoxification mechanisms are not differently active in any of the three GMS groups.

Our new observation that postload glucose levels are closely associated with α-dicarbonyl formation is of high clinical relevance because of the current developments in the field of glucose-lowering therapies. Dipeptidyl peptidase-4 inhibitors form a very new treatment strategy that has been shown to regulate postprandial glucose concentrations (35). Whether dipeptidyl peptidase-4 inhibitors can reduce α-dicarbonyls is unknown. In addition, the bionic pancreas is a state-of-the-art intervention that has been demonstrated to regulate glycemic control very strictly in type 1 diabetes (36) and may prove valuable in type 2 diabetes as well. Directly lowering α-dicarbonyl levels may also be a mechanism to reduce postprandial carbonyl stress and the putative association with vascular damage long-term. One intervention that is currently highly under investigation is pyridoxamine. Pyridoxamine is a chemical scavenger of reactive α-dicarbonyls and has been shown to inhibit formation of AGEs. Several experimental and clinical studies have already demonstrated beneficial effects of pyridoxamine with regard to diabetes microvascular complications (37–39).

The major strengths of this study are that we were able to perform our analyses in a large and well-defined cohort study, and in addition, we measured plasma α-dicarbonyls with state-of-the-art techniques based on ultra-performance liquid chromatography–tandem mass spectrometry. There are also a few limitations of this study. First, individuals with known type 2 diabetes did not undergo an OGTT, while they had higher fasting levels of α-dicarbonyl compounds compared with the patients with type 2 diabetes who did undergo a full OGTT. Therefore, their α-dicarbonyl levels during the OGTT are expected to increase even more than in newly diagnosed subjects, indicating that our observations may be an underestimation of the true effect in type 2 diabetes. Furthermore, the glucose load in the OGTT is not completely comparable with postprandial glucose excursions. For investigation of the effect of postprandial glucose excursions on α-dicarbonyl levels, a mixed-meal test needs to be done, although it has been described that the level of glycemia 2 h after an OGTT is closely related to the level of glycemia after a standardized meal (40). Moreover, a major advantage of the OGTT used in this study is that it allowed us to specifically investigate the hypothesis that glucose spikes cause formation of MGO without confounding of postprandial changes in lipid and protein levels.

In conclusion, we found that significant increases of MGO, GO, and 3-DG levels occurred during an OGTT in individuals with IGM and type 2 diabetes in comparison with control subjects. These increases were strongly associated with postload glucose excursions. These findings, together with the known harmful biological effects of these α-dicarbonyls, underline the potential importance of dicarbonyl stress as a functional candidate to explain the increased risk of diabetes complications in individuals with postprandial hyperglycemia. Prospective analyses on micro- and macrovascular complications are necessary to associate our current findings with vascular outcome.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. D.E.M. and N.M.H. researched data, contributed to discussion, and wrote and edited the manuscript. J.L.S. performed laboratory analyses and reviewed and edited the manuscript. C.J.v.d.K., M.M.v.G., C.D.S., and C.G.S. contributed to discussion and reviewed and edited the manuscript. C.G.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

  • Received November 3, 2014.
  • Accepted January 30, 2015.

References

  1. ↵
    1. Forbes JM,
    2. Cooper ME
    . Mechanisms of diabetic complications. Physiol Rev 2013;93:137–188pmid:23303908
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. de Vegt F,
    2. Dekker JM,
    3. Ruhé HG, et al
    . Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926–931pmid:10491751
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Beisswenger P,
    2. Heine RJ,
    3. Leiter LA,
    4. Moses A,
    5. Tuomilehto J
    . Prandial glucose regulation in the glucose triad: emerging evidence and insights. Endocrine 2004;25:195–202pmid:15758245
    OpenUrlCrossRefPubMed
  4. ↵
    1. The Diabetes Control and Complications Trial Research Group
    . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986pmid:8366922
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. UK Prospective Diabetes Study (UKPDS) Group
    . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853pmid:9742976
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Rohlfing CL,
    2. Wiedmeyer HM,
    3. Little RR,
    4. England JD,
    5. Tennill A,
    6. Goldstein DE
    . Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275–278pmid:11815495
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Donahue RP,
    2. Abbott RD,
    3. Reed DM,
    4. Yano K
    . Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36:689–692pmid:3569669
    OpenUrlAbstract/FREE Full Text
    1. Lowe LP,
    2. Liu K,
    3. Greenland P,
    4. Metzger BE,
    5. Dyer AR,
    6. Stamler J
    . Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163–169pmid:9118765
    OpenUrlAbstract/FREE Full Text
    1. DECODE Study Group; European Diabetes Epidemiology Group
    . Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617–621pmid:10466661
    OpenUrlCrossRefPubMedWeb of Science
    1. Coutinho M,
    2. Gerstein HC,
    3. Wang Y,
    4. Yusuf S
    . The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–240pmid:10333939
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Balkau B,
    2. Shipley M,
    3. Jarrett RJ, et al
    . High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360–367pmid:9540016
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Hanefeld M,
    2. Fischer S,
    3. Julius U, et al
    . Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–1583pmid:8960845
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Cavalot F,
    2. Petrelli A,
    3. Traversa M, et al
    . Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813–819pmid:16352690
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Brouwers O,
    2. Niessen PM,
    3. Miyata T, et al
    . Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia 2014;57:224–235pmid:24162587
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Giacco F,
    2. Du X,
    3. D’Agati VD, et al
    . Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 2014;63:291–299pmid:24062246
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Berner AK,
    2. Brouwers O,
    3. Pringle R, et al
    . Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012;55:845–854pmid:22143324
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Duran-Jimenez B,
    2. Dobler D,
    3. Moffatt S, et al
    . Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 2009;58:2893–2903pmid:19720799
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Bierhaus A,
    2. Fleming T,
    3. Stoyanov S, et al
    . Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012;18:926–933pmid:22581285
    OpenUrlCrossRefPubMed
  19. ↵
    1. Tikellis C,
    2. Pickering RJ,
    3. Tsorotes D, et al
    . Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 2014;63:3915–3925pmid:24812427
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Beisswenger PJ,
    2. Howell SK,
    3. O’Dell RM,
    4. Wood ME,
    5. Touchette AD,
    6. Szwergold BS
    . alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001;24:726–732pmid:11315838
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Du H,
    2. van der A DL,
    3. van Bakel MM, et al
    . Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am J Clin Nutr 2008;87:655–661pmid:18326604
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Hanssen NM,
    2. Engelen L,
    3. Ferreira I, et al
    . Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. J Clin Endocrinol Metab 2013;98:E1369–E1373pmid:23780372
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Scheijen JL,
    2. Schalkwijk CG
    . Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. Clin Chem Lab Med 2014;52:85–91pmid:23492564
    OpenUrlPubMed
  24. ↵
    1. Allison DB,
    2. Paultre F,
    3. Maggio C,
    4. Mezzitis N,
    5. Pi-Sunyer FX
    . The use of areas under curves in diabetes research. Diabetes Care 1995;18:245–250pmid:7729306
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. van Greevenbroek MM,
    2. Jacobs M,
    3. van der Kallen CJ, et al
    . The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Invest 2011;41:372–379pmid:21114489
    OpenUrlCrossRefPubMed
  26. ↵
    1. Levey AS,
    2. Stevens LA,
    3. Schmid CH, et al, .; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
    . A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612pmid:19414839
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Jacobs M,
    2. van Greevenbroek MM,
    3. van der Kallen CJ, et al
    . Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009;39:437–444pmid:19397692
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. El-Osta A,
    2. Brasacchio D,
    3. Yao D, et al
    . Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205:2409–2417pmid:18809715
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Brouwers O,
    2. Niessen PM,
    3. Ferreira I, et al
    . Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 2011;286:1374–1380pmid:21056979
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Kang Y,
    2. Edwards LG,
    3. Thornalley PJ
    . Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. Leuk Res 1996;20:397–405pmid:8683979
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Kalapos MP
    . Where does plasma methylglyoxal originate from? Diabetes Res Clin Pract 2013;99:260–271pmid:23206674
    OpenUrlCrossRefPubMed
  32. ↵
    1. Schalkwijk CG,
    2. van Bezu J,
    3. van der Schors RC,
    4. Uchida K,
    5. Stehouwer CD,
    6. van Hinsbergh VW
    . Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett 2006;580:1565–1570pmid:16487519
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Thornalley PJ
    . The glyoxalase system in health and disease. Mol Aspects Med 1993;14:287–371pmid:8277832
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Rabbani N,
    2. Thornalley PJ
    . Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011;22:309–317pmid:21335095
    OpenUrlCrossRefPubMed
  35. ↵
    1. Vora J,
    2. Bain SC,
    3. Damci T, et al
    . Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab 2013;39:6–15pmid:23022130
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Russell SJ,
    2. El-Khatib FH,
    3. Sinha M, et al
    . Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313–325pmid:24931572
    OpenUrlCrossRefPubMed
  37. ↵
    1. Williams ME,
    2. Bolton WK,
    3. Khalifah RG,
    4. Degenhardt TP,
    5. Schotzinger RJ,
    6. McGill JB
    . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27:605–614pmid:17823506
    OpenUrlCrossRefPubMedWeb of Science
    1. Tanimoto M,
    2. Gohda T,
    3. Kaneko S, et al
    . Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 2007;56:160–167pmid:17224327
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Degenhardt TP,
    2. Alderson NL,
    3. Arrington DD, et al
    . Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939–950pmid:11849448
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Wolever TM,
    2. Chiasson JL,
    3. Csima A, et al
    . Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998;21:336–340pmid:9540012
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Add to Selected Citations

Post–Glucose Load Plasma α-Dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study
Dionne E. Maessen, Nordin M. Hanssen, Jean L. Scheijen, Carla J. van der Kallen, Marleen M. van Greevenbroek, Coen D. Stehouwer, Casper G. Schalkwijk
Diabetes Care May 2015, 38 (5) 913-920; DOI: 10.2337/dc14-2605
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section